The Medical Advisor

A little over a year ago, Joseph Coates was told there was only one thing left to decide. Did he want to die at home, or in the hospital? Coates, then 37 and living in Renton, Wash., was barely conscious. For months, he had been battling a rare blood disorder called POEMS syndrome, which had left him with numb hands and feet, an enlarged heart and failing kidneys. Every few days, doctors needed to drain liters of fluid from his abdomen. He became too sick to receive a stem cell transplant — one of the only treatments that could have put him into remission. “I gave up,” he said. “I just thought the end was inevitable.” But Coates’s girlfriend, Tara Theobald, wasn’t ready to quit. So she sent an email begging for help to a doctor in Philadelphia named David Fajgenbaum, whom the couple met a year earlier at a rare disease summit. By the next morning, Dr. Fajgenbaum had replied, suggesting an unconventional combination of chemotherapy, immunotherapy and steroids previously untested as a tr...

Your choice of cooking oil can make a profound difference in your health. I’ve often warned against the use of soybean oil. Not only is partially hydrogenated soybean oil loaded with trans fat, which has been linked to heart disease,1 it’s also a source of an omega-6 fat called linoleic acid (LA), which is highly susceptible to oxidation and is typically from GMO seeds. An estimated 94% of the soybeans grown in the U.S. are genetically engineered (GE) to tolerate herbicides, primarily glyphosate (the active ingredient in Monsanto/Bayer's Roundup), which cannot be washed off. As a result, most soybean-based products are contaminated with glyphosate, which compounds their toxicity. The problem results once you start to digest this fat, as you break it down into harmful sub-components called advanced lipid oxidation end products (ALEs) and oxidized LA metabolites (OXLAMs) that can cause significant damage at the cellular level. For example, an ALE called 4HNE is a mutagen known to ca...

The doctor’s office was silent, save for the rhythmic ticking of the wall clock. The air felt heavy, charged with an unspoken weight. As the oncologist cleared his throat, the words that followed shattered the fragile hope clinging to the room. "Stage four." A pause. A breath. A death sentence wrapped in sterile, clinical detachment. There it was—cancer. The monster that had stolen loved ones, that had turned strong men frail and vibrant souls dim. And now, it had come for him. The world blurred at the edges, but the message was clear: conventional treatments would, at best, buy time. Not a cure, just an extension—one measured in months, not years. Chemo, radiation, the cycle of sickness, and the slow decay that followed. But he wasn’t ready to give in. Not like this. Not without a fight. He had a friend who was a veterinarian that suggested the drug.  Fenbendazole. A humble dog dewormer. A compound so unassuming, so ordinary, that it sounded absurd. But within its chemical s...

Here’s a concise and evidence-based overview of Ivermectin, Fenbendazole, Mebendazole, and their potential relationship to Multiple Myeloma (MM), a cancer of plasma cells, as of March 26, 2025. This response draws on recent studies and anecdotal reports while acknowledging the current limitations of the evidence. Ivermectin and Multiple Myeloma Ivermectin, an FDA-approved antiparasitic drug, has shown preclinical promise against MM: 2024 Study (Yang Song et al.) : Published in World Journal of Clinical Oncology , this study assessed Ivermectin’s potential against the high-risk t(4;14) MM subtype. Using bioinformatics, molecular docking, and in vitro experiments, it found Ivermectin inhibited MM cell growth and induced apoptosis via the NF-κB signaling pathway. Key genes linked to this subtype were identified, suggesting Ivermectin as a candidate for repurposing. 2023 Study (PubMed) : Ivermectin synergized with proteasome inhibitors (e.g., bortezomib) in vitro and in vivo, inhibiting p...